Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients

Exp Clin Transplant. 2012 Jun;10(3):258-62. doi: 10.6002/ect.2010.0127.

Abstract

Objectives: To investigate the efficacy and safety of an immunosuppressive regimen of steroid avoidance in combination with induction therapy and tacrolimus in liver transplant recipients.

Materials and methods: Eighty-two adult liver transplant recipients were randomized into 2 groups: standard protocol group (n=41) in which steroids were withdrawn 3 months after the operation, and a 24-hour steroid avoidance group (n=41) in which steroids were eliminated within 24 hours. The incidence of acute rejections, infections (bacterial, fungal, and cytomegalovirus), and metabolic complications were analyzed between the groups.

Results: The incidence of early posttransplant diabetes mellitus and the average dosage of insulin consumption among diabetic recipients were significantly higher in recipients in the standard protocol group than in the 24-hour avoidance group (P < .05). In addition, the incidence of hypertension and infection during the follow-up were also higher in patients of the standard protocol group (P < .05). The incidence of hypertension in the early posttransplant period, hyperlipemia, and acute rejection during the follow-up were comparable between the groups (P > .05).

Conclusions: Twenty-four hour steroid avoidance combined with induction therapy and tacrolimus maintenance is a safe and efficient immunosuppression strategy that can significantly reduce posttransplant infections and other complications owing to long-term use of steroids, without increasing the risk of acute rejection.

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • China
  • Diabetes Mellitus / epidemiology
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Graft Rejection / epidemiology
  • Graft Rejection / prevention & control*
  • Humans
  • Hypertension / epidemiology
  • Immunosuppressive Agents / therapeutic use*
  • Incidence
  • Kaplan-Meier Estimate
  • Liver Transplantation / immunology*
  • Liver Transplantation / mortality
  • Male
  • Middle Aged
  • Recombinant Fusion Proteins / therapeutic use*
  • Risk Factors
  • Steroids / therapeutic use*
  • Tacrolimus / therapeutic use*
  • Time Factors
  • Withholding Treatment*

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Steroids
  • Basiliximab
  • Tacrolimus